Table 1. Patients enrolled in the BEVA2007 trial undergone the immune-biological monitoring.

	mPE	mPEBev
Patient number	12	47
Age	69 (range 59–83)	62 (range 33–82)
Gender
Male	10	37
Female	2	10
Hystology
Adenocarcinoma	5	32
Squamous	4	6
Undifferentiated	2	4
Not specified	1	4